The agenda for the meeting was:
1. Election of Chairman of the Meeting.
2. Report on the Company’s activities during the past year.
3. Presentation of audited annual report with Auditor’s statement for approval.
4. Resolution on application of profits or covering of losses as per the adopted annual report.
5. Election of board members.
6. Election of auditor.
7. Proposals from the board of directors and/or shareholders.
7.1. Proposal to amend the articles of association for incentive remuneration to the management
8. Proposal to authorize the chairman of the meeting
9. Any further business
A summary of the resolutions follows below. All resolutions were passed with the required majority.
The Board of Directors recommended that the audited annual report was adopted.
The audited annual report was approved unanimously by all votes represented at the general meeting.
The Board of Directors proposed that the consolidated loss for the year of 30,390 TDKK was carried forward to next year through recognition in retained earnings.
The proposal was approved unanimously by all votes represented at the general meeting.
All Members of the Board of Directors were up for election.
All members of the Board of Directors were re-elected so that the Board of Directors would consist of the following members:
Frank Knudsen
Gunnar Magnus Severus Modée Persson
Peter Buhl
Steen Meier Knudsen
Niels Johansen
Jørgen Bardenfleth
The proposal was approved unanimously by all votes represented at the general meeting.
The Board of Directors proposed that, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB was re-appointed as the Company’s auditor.
The proposal was approved unanimously by all votes represented at the general meeting.
The board of directors proposes that the company’s general guidelines on incentive remuneration to the management in accordance with the Danish Companies Act section 139 is amended, so that the following text is deleted, as this part is not relevant anymore:
“Warrant grant 2017
On June 14, 2016 the board of directors resolved that 696,220 warrants in total issued by the board of directors to the executive management board and the board of directors of the Company on respectively December 14, 2014 and February 18, 2016 were invalid as the Company had not prior to such issues duly adopted and obtained approval from the general meeting of incentive remuneration guidelines pursuant to the Danish Companies Act Section 139. Consequently, in order to compensate holders of the cancelled warrants and subject to approval from the general meeting, the company expects to grant a number of warrants to each holder of the cancelled warrants corresponding to the cancelled warrants. The estimated Black-Scholes value of this warrant grant to members of the board of directors and members of the executive management is DKK 16,013,060.”
The proposal was approved unanimously by all votes represented at the general meeting.
The board of directors proposes that the general meeting authorizes attorney-at-law Lars Lüthjohan Jensen to register the resolutions made with the Danish Business Agency and in this connection to make such corrections and amendments to the approved documents which may be required by the Danish Business Agency for registration thereof.
The proposal was approved unanimously by all votes represented at the general meeting.
About MPI’s multiple biomarker called Drug Response Predictor – DRP
MPI’s DRP is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP has been tested in 37 trials, where 29 trials showed that drug-specific DRP Biomarkers could predict which patients responded well to the treatment. The DRP platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anti-cancer drug. In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP is a Big Data tool based on messenger RNA.
The DRP platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.
About MPI
Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP technology. MPI’s exceptional opportunity to personalize cancer treatment – begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI’s DRP tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,100 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.
For further information, please contact:
CEO, Peter Buhl Jensen, MD, PhD Ulla Hald Buhl, IR & Communication
E-mail: [email protected] E-mail: [email protected]
Telephone: +45 21 60 89 22 Telephone +45 21 70 10 49
This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 24 2018.
Certified Advisor: Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sweden
